We are live on ! Find out more
VMI

VHCP Management III Portfolio holdings

AUM $504M
1-Year Est. Return 683.12%
This Fund
S&P 500
This Quarter Est. Return
+363.21%
1 Year Est. Return
+683.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$504M
AUM Growth
+$342M
Cap. Flow
+$112M
Cap. Flow %
22.32%
Top 10 Hldgs %
90.41%
Holding
26
New
9
Increased
2
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$70.7M
2
ETNB
89bio
ETNB
+$26.7M
3
RLMD icon
Relmada Therapeutics
RLMD
+$23.3M
4
ADVM
Adverum Biotechnologies
ADVM
+$8.34M
5
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$8.29M

Top Sells

Rank Stock Value
1
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$15.9M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$9.85M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.76M
5
AXSM icon
Axsome Therapeutics
AXSM
+$2.56M

Sector Composition

Rank Sector Weight
1 Healthcare 97.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LJPC
26
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-1,251,898
Closed -$11M
1
2

Similar funds

BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return

VHCP Management III's Q4 2019 Portfolio in Review

As of Q4 2019, VHCP Management III held 26 positions worth $504M, up 211% from $162M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

VHCP Management III deployed $112M of net new capital in Q4 2019, opening 9 new positions and adding to 2 existing holdings. Its largest new stake was 89bio: 958,765 shares worth $25.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $9.85M trimmed.

  • VHCP Management III's largest Q4 2019 buy was 89bio: 958,765 shares worth $25.2M.
  • VHCP Management III added most to Constellation Pharmaceuticals, Inc. in Q4 2019, an estimated $70.7M increase.
  • VHCP Management III's biggest Q4 2019 reduction was Protagonist Therapeutics, cutting an estimated $9.85M.
  • VHCP Management III fully exited Ra Pharmaceuticals, Inc. Common Stock in Q4 2019, selling an estimated $15.9M.
  • VHCP Management III's ten largest holdings make up 90% of its $504M portfolio in Q4 2019.
  • VHCP Management III opened 9 new positions and closed 8 in Q4 2019.
  • VHCP Management III's portfolio value rose 211% quarter-over-quarter to $504M.

Based on VHCP Management III's 13F filing for Q4 2019, filed 13 Feb 2020.